glp 1 thanksgiving Less gorging, more gratitude: How GLP-1s are changing The holidays usually mean indulging

A patient with lower GLP1R pathway activation might benefit more from tirzepatide's dual-peptide action (which targets both GLP-1 and GIP receptors), while someone with strong GLP1R sensitivity may achieve excellent results with standard semaglutide timing

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg with semaglutide 2.4 mg

In this context, GLP-1 agonists represent a potentially valuable tool within a multimodal treatment approach, particularly for patients who have not achieved adequate weight loss through lifestyle modification alone

Comment below REFERENCES Matrescence to Menopause: a Second Window For Female Longevity British Medical Society Advice on Use of Incretin-Based Therapy in Women on HRT McKinsey Health Institute Closing the womens health gap: A $1 trillion opportunity UK Womens Health Strategy Nature Medicine Reviews on GLP-1 receptor agonists and metabolic health NEJM GLP-1 receptor agonists and cardiometabolic outcomes NHS MBRRACE-UK Maternal mental health and postnatal outcomes reports FDA GLP-1 receptor agonists: prescribing information and drug interaction guidance European Medicines Agency (EMA) GLP-1 receptor agonists safety information